Incyte Corporation

Incyte Corp. is an American biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics in hematology, oncology, and inflammation and autoimmunity, generating $5.14 billion in revenue in fiscal 2025. The company built its franchise on Jakafi (ruxolitinib), the first FDA-approved JAK inhibitor for myelofibrosis, and is now executing a deliberate transition toward a diversified, multi-product portfolio ahead of Jakafi's loss of exclusivity in 2028.

This is a story about managing a patent cliff at a company with the balance sheet and pipeline to do it thoughtfully. Incyte enters its transition with $3.6 billion in cash and investments, a drug that still grew 11% in its fourteenth year on the market, and a pipeline dense enough to support four new product launches over the next twelve months. No biopharma transition is clean — the sequencing risk here is whether the portfolio's growth engines reach scale before the Jakafi cliff hits. The file turns on that question.

The bull case rests on povorcitinib, an oral JAK1 inhibitor with positive Phase 3 data in hidradenitis suppurativa and vitiligo and a third readout in prurigo nodularis expected by year-end 2026. The bear case notes that Jakafi generated roughly 71% of 2025 net product sales, that the non-Jakafi portfolio has yet to produce a product above $700 million, and that biotech pipelines fail more often than they succeed. Both sides have data. The next eighteen months will deliver much of the evidence needed to settle the argument.